Cafepharma | Pharmaceutical Sales, Medical Sales, Lab Sales

Cafepharma Today

November 29 2023 - FDA names chief scientist Bumpus as Woodcock’s successor

FDA names chief scientist Bumpus as Woodcock’s successor
FDA launches probe of malignancies linked to CAR-T therapies
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Lilly puts potential $660M on the line for protein-protein interaction blockers
*please scroll down for all the latest news*

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

Pharmaphorum

Monday, November 13, 2023 - 10:03am

tags:

Eli Lilly, AHA, siRNA, lipoprotein(a), cardiovascular disease, lepodisiran

Aclaris shares plummet on terminating development of rheumatoid arthritis drug

Reuters

Monday, November 13, 2023 - 10:00am

tags:

Aclaris, Therapeutics, rheumatoid arthritis, clinical trials, zunsemetinib

IO Biotech concludes subject enrollment in melanoma vaccine trial

Clinical Trials Arena

Monday, November 13, 2023 - 9:57am

tags:

IO Biotech, clinical trial, melanoma, vaccines

Basilea continues pipeline fill-up by paying Pfizer $37M for Amplyx antifungal

Fierce Biotech

Monday, November 13, 2023 - 9:55am

tags:

Pfizer, Basilea, Amplyx, antifungals

Wegovy cuts risk of heart attacks in milestone cardiovascular trial

Stat

Sunday, November 12, 2023 - 9:32pm

tags:

Wegovy, Novo Nordisk, clinical trials, cardiovascular disease

Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?

Motley Fool

Sunday, November 12, 2023 - 9:30pm

tags:

Merck, Bristol Myers Squibb, antibody-drug conjugate

First look at Verve study data offer base editing ‘proof of principle’

BioPharma Dive

Sunday, November 12, 2023 - 9:27pm

tags:

Verve Therapeutics, heart disease, gene editing

Takeda snares approval for all-comer gastric cancer drug

Medical Marketing and Media

Sunday, November 12, 2023 - 9:23pm

tags:

Takeda, Fruzaqla, colorectal cancer

Lilly’s Zepbound vs. Novo’s Wegovy: The Weight-Loss Drug Race Has Officially Started

Motley Fool

Sunday, November 12, 2023 - 9:21pm

tags:

Eli Lilly, Zepbound, Novo Nordisk, Wegovy, weightloss

Skyrizi goes sky-high in October among Rx, OTC pharma brands

Medical Marketing and Media

Sunday, November 12, 2023 - 9:19pm

tags:

Boehringer Ingelheim, AbbVie, Skyrizi, DTC advertising, pharma advertising

Acutus laying off 65% of employees to focus solely on Medtronic heart device deal

Medtech Dive

Friday, November 10, 2023 - 12:29pm

tags:

Acutus Medical, Medtech, Medtronic, layoffs, electrophysiology mapping, atrial fibrillation

Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.

Motley Fool

Friday, November 10, 2023 - 12:19pm

tags:

Eli Lilly, donanemab, tirzepatide, mirikizumab, lebrikizumab, pirtobrutinib

Vaccitech reemerges as Barinthus with hep B data showing declines in infection levels

Fierce Biotech

Friday, November 10, 2023 - 12:05pm

tags:

Barinthus Biotherapeutics, Vaccitech, clinical trials, hepatitis B

Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry

BioSpace

Friday, November 10, 2023 - 10:14am

tags:

Neurocrine, neuropsychiatric, clinical trials, focal onset seizures, major depressive disorder, NBI-921352, NBI-1065846

Takeda Wins First FDA Approval for Ultra-Rare Blood Clotting Disease

BioSpace

Friday, November 10, 2023 - 10:12am

tags:

Takeda, FDA, ADAMTS13, Adzynma, cogenital thrombocytopenic purpura

Novo Nordisk sets aside $6bn to boost production capacity

Pharmaphorum

Friday, November 10, 2023 - 10:11am

tags:

Novo Nordisk, diabetes, obesity, drug manufacturing

European regulator endorses high-dose version of Bayer eye drug Eylea

Reuters

Friday, November 10, 2023 - 10:09am

tags:

Bayer, EMA, Eylea, Roche

Inovio, with path to market opening up, drafts accelerated approval talking points ahead of FDA meeting

Fierce Biotech

Friday, November 10, 2023 - 10:08am

tags:

Inovio Pharmaceuticals, Rare Diseases, INO-3107, DNA, FDA

AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial

Clinical Trials Arena

Friday, November 10, 2023 - 10:06am

tags:

AstraZeneca, clinical trials, Imfinzi, hepatocellular carcinoma

Novartis’ urticaria drug meets all endpoints in Phase III trials

Clinical Trials Arena

Friday, November 10, 2023 - 10:05am

tags:

Novartis, remibrutinib, chronic spontaneous urticaria, clinical trials

Pages

Latest CP Wire Articles

First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study

Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth

Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Sapio Sciences launches new drug discovery platform

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Why Medical and Pharma Sales Reps Should Start Their Own Senior Care Business

Bend Bioscience Adds Capacity and Technology Offerings with the Addition of New Process and Manufacturing Science Facility

Eastman introduces new excipient to formulate poorly soluble API

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more

PharmaBlock Receives 2023 ACS CMO Excellence in Green Chemistry Award

Latest Pharmagather Articles

Drug Channels News Roundup, November 2023: My $0.02 on Express Scripts’ Cost-Based Pricing, Mark Cuban vs. PBMs, Dual-WAC Strategies, Pharmacy Shakeout, and Adam vs. Rocky

Drug Channels

Simplify and Accelerate Benefits Verification with a Fully Integrated, Adaptable Platform

Drug Channels

Medicare Part D in 2024: Mapping Large Chains' Position in 2024’s Preferred Pharmacy Networks

Drug Channels

Drug Channels Outlook 2024 (NEW Live Video Webinar)

Drug Channels

Four Trends That Are Shaping the Future of Market Access

Drug Channels

FDA’s OPDP Issues Two New Untitled Letters

eye on fda

Vertical Integration Lessons: The Economics and Strategies of Hospital-Owned Specialty Pharmacies

Drug Channels

Is Your Hub Partner Missing the Therapeutic Area Expertise You Need?

Drug Channels

Drug Channels News Roundup, October 2023: CVS & Humira Biosimilars, GLP-1 G2N Bubble, 340B Abuses, Rite Aid's Endgame, Mark Cuban Update, and an Epic Meetup

Drug Channels